News & Events

09.08.2019

SanoLiBio goes Canada.

13 EUROPEAN COMPANIES SELECTED UNDER EIT HEALTH GO GLOBAL PROGRAM TO REACH CANADIAN MARKET AND HEALTHTECH INNOVATION HUBS

Following an intensive selection process through a dedicated European-Canadian jury, thirteen European companies are laureates of the 2019 edition of the GoGlobal Canada program and will benefit from a unique gateway to Canada. The program will enable the start-ups & SMEs to enter three recognised Canadian innovation hubs which can act as major stepping stones into the North American market and initiate significant collaboration opportunities with qualified stakeholders.

The programme will run over 2019 and is set up as followed:
– preparatory workshop for Canada during the European medtech event MedFIT, taking place during 25-26 June in Lille, France. It will be the opportunity for companies to meet the local partners and have a first level of understanding of the local market opportunities;
– a ten days’ immersion roadshow in the fall in British Columbia, Ontario and/or Quebec provinces to meet the local players (support structures, KOLs and potential partners), gain first visibility and traction and understand the local innovation trends and healthcare market access opportunities;
– final event and networking between the European and Canadian delegations during the MEDICA Fair in Düsseldorf, Germany, on 18-21 November to enable SMEs to share their experiences and benefit from an international outreach.

The selected SMEs are:

AdEchoTech
Innovative French SME operating in the MedTech/Telemedicine sector. Designer and manufacturer of remote robotic ultrasound systems capable of providing ultrasound diagnosis from distance in real time thanks to internet or satellite connections.

ALREH MEDICAL
Alreh Medical designs and manufactures rehabilitation equipment. It is specialized in physical and cognitive rehabilitation devices for elderly (activLife brand) and in rehabilitation equipment for paraplagic users (iStander , Activ+, Activ Drive brands).

evolucare
Evolucare is a French family owned SME in healthcare IT. It has been successfully in business for 30 years in France and French-speaking countries of Africa. It has quite a large portfolio for a small company (ranging from EHR, Medical Imaging, Critical Care, Social Care to Analytics) and have invested intensively in innovation, in particular in AI.

HEMCHECK
Hemcheck Sweden AB is a public (Nasdaq First North) medical technology company and is based on an invention for POC detection of hemolysis in blood samples by Dr Mathias Karlsson. HemCheck is manufacturing and marketing a CE-marked concept, HELGE™, that detects hemolysis in blood samples in vacuum tubes and blood gas syringes during blood sampling at the point of care, with the aim to improve healthcare quality and patient flows while reducing costs

METAFORA
Metafora develops diagnostic tests that detect abnormalities in cellular metabolism. Using patented reagents that quantify cell nutrient transporters, coupled with powerful algorithms, the platform is able to detect abnormal nutrient consumption linked to illnesses such as neuro-metabolic diseases or cancer. METAFORA already launched METAglut1 on the European market, a CE-marked test for a neuro-metabolic condition, GLUT1DS.

MILVUE
Milvue is an innovative and reliable artificial intelligence medical device for real-time diagnostic assistance on emergency radiology, and more particularly on X-Rays. Milvue automates the detection of X-Rays related abnormalities of an emergency workflow. The mission is to improve reliability and fasten diagnosis by reducing errors and time to diagnosis, all together with improving communication between physicians.
Mindpax: Mindpax is an early stage digital medicine company that is building comprehensive digital therapy for severe psychiatric diseases using new biomarkers, digital phenotyping and long-term monitoring of patients.

myPatientSpace
myPatientSpace is a scalable eHealth platform enabling healthcare providers and life science companies to provide digital engagement for their patients. The solution is easily branded and rapidly configured for any pathway. myPatientSpace app is the patient’s treatment companion, bringing together education, consent, tasks, patient data and provider collaboration. The smart engine automates engagement and tasks across the patient’s pathway – supporting better outcomes, improving patient experience, gathering data, reducing costs and driving efficiency in care.

Rheonova
Rheonova has developed Rheomuco which is an IVD medical device that use lung mucus rheology to evaluate lung congestion. Rheonova delivers a point-of-care test within 10 min and €10, with a quantitative biophysical marker and a specificity above 80%. It develops a series of test (diagnostic, prediction, companion) for chronic obstructive diseases like COPD, CF (Cystic Fibrosis), Severe Asthma, Bronchiectasis.

SanoLiBio
SanoLiBio is focusing on the enrichment of rare cells taken from liquid biopsy such as circulating tumor cells (CTCs). We have developed a fully automated enrichment platform to make CTCs available for early stage cancer diagnostic, next-generation sequencing and drug development.

SYSTERV
Systerv has developed DoctorsHello which is an interactive “Connect-Collaborate-Share” ecosystem based on a network of collaborators (healthcare professionals /general users/ Healthcare businesses and policy decision makers), ensuring quality services. The ecosystem supports collaboration, provision of added-value services and easier reach to medical discovery through rich data, research and education.

TONGUE LAB
Tongue develops the TRP, first custom-made device for tongue functions and breathing re-education. Markets: Medical : cure of snoring, obstructive sleep apnea (OSA), prevention of comorbidities; Dental: Orthodontics, bruxism; nasal breathing; Wellness : sports and work performance.
WORLDISH: Worldish helps healthcare professionals and patients overcome their language barriers through its digital communication tool Helen. Helen provides translation support and documentation support using global healthcare protocols and standards.

The program is run by three leading healthtech clusters in Europe:

Medicen Paris Region
Medicen Paris Region is a competitiveness cluster for innovative health technologies, with national and international scope. With more than 450 companies, research centres, universities, hospitals and local authorities as members, it aims to position the Paris region as Europe’s leading healthcare cluster. It focuses on five strategic areas: biological diagnostics, diagnostic and interventional imaging, innovative biotherapies, digital health and technotherapies.

Medical Valley
The Medical Valley European Metropolitan Region Nuremberg is an internationally leading cluster in the medical engineering sector. The area is home to highly specialized research facilities, global players and many upcoming companies.
Being convinced that innovative technologies and services will improve healthcare in the coming decades, key players from business, science, healthcare and politics have joined together in the Medical Valley EMN to unite their resources as a cluster to create synergies. The resulting accumulated technology and problem-solving competency is used to develop and market effective solutions tailored to suit global market demands.

Medicalps
MEDICALPS is non-profit organization and a healthcare industry cluster (biotechnologies, medical devices, e-heath) located in the heart of French Alps. MEDICALPS aims to accelerate the time to international market and to enhance connections within the local healthcare ecosystem.
The cluster gathers over 100 members including research and hospital facilities, local authorities and a vast majority of startups and SMEs designing and manufacturing medical devices. The cluster has also the support of large companies such as BD, Roche diagnostic and Medtronic.
The ecosystem is represented by a dense network of companies in the field of surgical navigation system, computer assisted surgery (especially orthopaedics), point-of-care devices, IVD, drug delivery systems and other connected e-health systems.

26.06.2019
SanoLiBio pitches at BANSON pitch evening
Today, we will share our view on the prospectives of liquid biopsy and how we will establish circulatin tumor cells as THE early stage cancer biomarker Interested to meet the team? Get in touch: info@sanolibio.com

14.06.2019
SanoLiBio announces that its negative selection cell enrichment assay has been validated
The team of SanoLiBio achieved another major milestone today. The performance of our Walderbach platform has been validated by an independent expert. Check our Scientific papers section for more details.

12.06.2019
Liquid Biopsy Pioneer SanoLiBio announces Nomination of its Advisory Board Munich

SanoLiBio GmbH, a leading player in liquid biopsy innovation, announced today the nomination of its advisory board: Members are Bruno Steis (Gray Fox Consulting GmbH), Dr. Peter Frost (PELOBiotech GmbH) and Dr. Bernhard Polzer (ITEM Fraunhofer). The long-standing partner at Siemens Venture Capital and former CEO of inge GmbH Bruno Steis acts as chairman. Board Member Dr. Peter Frost serves as expert in the Life Sciences sector by supervising the Sales&Marketing activitities. Dr. Bernhard Polzer contributes to the success of Sanolibio as a clinical networker and with his expert knowledge on cancer diagnostics based on his leading position at Fraunhofer ITEM.

The board supports the management to position SanoLiBio for further growth by bringing deep domain expertise in company building, sales and marketing and R&D to the table. It facilitates the current fundraising process as well.

“To enrich circulating rare cells, such as circulating tumor cells is one of the key factors in the growing market of liquid biopsy”, says board member Dr. Peter Frost, CEO of PELOBiotech, one of the leading cell culture companies, outlining the need for technological innovations. SanoLiBio uses a novel magnetic bead cell separation procedure that allows high-sensitive detection of rare cells in blood samples. Based on the power of their technology, SanoLibio is confident to advance early diagnosis and prevention.

The company is seeking funding in order to introduce its enrichment platform “Walderbach” to the market in H1 2020.

About SanoLiBio GmbH

SanoLiBio focuses on the ultra-high enrichment of rare cells, such as circulating tumor cells, taken from liquid biopsy. The overall liquid biopsy market will grow to USD 10,7bn by 2026, a CAGR of 24.2%. Thereof, the sub-segment of cancer will grow with a CAGR of 52,4%. (Source: BCC Research, Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets October 2017).

The Medtech-Startup was founded 2017 located in Munich at the Biotech-Hotspot in Europe. CEO is Dr. Stefan Schreier who leads the company together with Timo Peter (COO) and Ulrich Lang (CTO).

About “Walderbach”

The company will introduce its fully automated cell enrichment platform, named “Walderbach”, as a new benchmark in rare cell isolation from 2020 onwards internationally. The platform allows early stage cancer diagnostic in a fast, reliable and affordable way for the very first time. The enrichment platform is named “Walderbach” after the CEO’s home town.

About the board
Bruno Steis (Chairman)

• In total 35 years professional experience in leading management functions, both in large corporations and technology start-ups
• Senior Investment Partner (9 years) at Siemens Venture Capital with responsibility for numerous investments in technology firms, incl. membrane manufacturer inge AG
• 40 years cumulated experience as Chairman/Member of Supervisory and Advisory Boards

Dr. Peter Frost (Member)
• More than 20 years experience in Sales & Marketing of Life Science products for basic and clinical research. Introduced successfully innovative Biotech companies in the European as well as US market (e.g. SpheroTec, Sirion Biotech, InSphero)
• Was involved in the market entry of StemCell´s RoboSep, a automated cell separation system
• Developed PELOBIOTECH GmbH to one of the leading cell culture companies

Dr. Bernhard Polzer (Member)
• More than 15 years’ experience in R&D and publication record on single cell analysis, liquid biopsy and cancer metastasis
• Background in human medicine and translation of new technologies in clinical applications
• Group leader „Cellular and Molecular Diagnostics“ at Division „Personalized Tumor Therapy“ of Fraunhofer Institute for Toxicology and Experimental Medicine, Regensburg

For Press Contacts: Timo Peter, COO
M: +49 172 8889848
E: timo.peter@sanolibio.com
www.sanolibio.com

08.04.2019
SanoLiBio will pitch at the 2019 Biotech Investors Day in Würzburg on April 8th, 2019. Do you want to meet? Don’t hesitate to contact us.
Learn more: www.biodeutschland.org/de/biotech-investors-day.html

29.10-02.11.2018
SanoLiBio will particpate in the 2018 Sino-Europe Innovation Week of Health Technology – “Innovation for Health” – event organized by International Co-Innovation Center for Advanced Medical Technology (iCCAMT). On this roadshow the team will present SanoLiBio’s rare cell enrichment platform to potential clients and investors in Shenzhen, Shanghai and Nanjing. Do you want to meet? Don’t hesitate to contact us.
Learn more: www.iccamt.com

26.10.2018
SanoLiBio will particpate in the Elevator Pitch Competition (EPiC) 2018 event organized by Hong Kong Science and Technology Parks Corporation (HKSTP). The team will pitch among 100 international start-ups in the elevator of and at Sky100, the hundreth floor of the International Commerce Centre tower. Do you want to meet? Don’t hesitate to contact us.
Learn more: www.hkstp.org/en

15-22.10.2018
SanoLiBio will particpate from Oct 15-20 in the US EIT Health GoGlobal programm organized by the Nürnberg Mecial Valley. The team will meet potential customers, partners and investors in New York and Boston. This will give SanoLiBio a major push towards our market entry USA and internationalization at all. Do you want to meet? Don’t hesitate to contact us.

18.07.2018
Today, the SanoLiBio team achieved a major milestone. Our first cell enricher single device has been shipped to our clinical partner Premise Diagnostic, Thailand.
The device will be primarily used to generate medical data and validate our process. Management expects to ship first products to customers H1 2020.

03.05.2018
SanoLiBio attends the Baker McKenzie Bio Tech Seminar “Investing in Biotech in Europe from Seed to Exit: Latest Trends”. Contact and meet us: info@sanolibio.com

27.03.2018
SanoLiBio has been selected to participate in the GoGlobal programm of the Medical Valley Nürnberg. The programms support innovative growth companies with advise on how to establish an international business, gives access to oversea customers and partners and organizes a roadshow to key regions. For SanoLiBio these are the US and Asia.

03.07.2017
SanoLiBio attends the 3rd Munich Life Science Pitch Day at the IZB. Contact and meet us: info@sanolibio.com

27.05.2017
SanoLiBio participates in the Start-up Challenge at Deutsche Biotechnologietage 2017 in Hannover.
SanoLiBio has been selected to pitch at the Start-up Challenge event at Deutsche Biotechnologietage 2017, 5. to 6. April in Hannover. We are looking forward to meeting you.